The triplet combination of nivolumab, relatlimab, and ipilimumab offered promising response rates and survival outcomes in patients with untreated advanced melanoma, according to preliminary data from the nonrandomized phase 1/2 RELATIVITY-048 trial (Abstract 9504). Although the results require confirmation in larger randomized trials, the 4-year overall survival (OS) rate seen with the triplet regimen compares favorably with other nivolumab-based combinations in this setting.
Health Professionals
Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma
Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
Targeted induction before immunotherapy shows limited benefit in advanced melanoma
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.